Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ciprofloxacin hydrochloride
Drug ID BADD_D00472
Description Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics.[A178870] It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] The first ciprofloxacin containing product was FDA approved on 22 October 1987.[L6463]
Indications and Usage For the treatment of the following infections caused by susceptible organisms: urinary tract infections, acute uncomplicated cystitis, chronic bacterial prostatitis, lower respiratory tract infections, acute sinusitis, skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections (used in combination with metronidazole), infectious diarrhea, typhoid fever (enteric fever), uncomplicated cervical and urethral gonorrhea, and inhalational anthrax (post-exposure).
Marketing Status Prescription; Discontinued
ATC Code J01MA02; S01AE03; S02AA15; S03AA07
DrugBank ID DB00537
KEGG ID D02216
MeSH ID D002939
PubChem ID 62999
TTD Drug ID D0O1WX
NDC Product Code 50090-3791; 17478-714; 43063-923; 68999-309; 70518-1278; 70518-1234; 50090-5628; 63187-150; 59390-217; 68071-2382; 62135-308; 52286-0005; 0078-0841; 50090-5671; 61442-222; 68788-8136; 53069-0180; 48589-0001; 51943-112; 45865-721; 12527-8513; 50419-754; 16714-653; 62704-0030; 53002-1320; 65862-076; 71901-602; 72789-006; 51672-4085; 50090-0881; 63629-8344; 50090-3130; 61314-656; 62991-2518; 38779-0534; 76420-045; 0065-0656; 63629-1010; 71610-159; 63629-7648; 50090-5373; 50090-5371; 70934-093; 68071-4139; 58032-0006; 72189-111; 52286-0015; 71335-2046; 65862-077; 62135-310; 16714-652; 66021-0003; 71335-1024; 49452-2080; 0404-7187; 55700-884; 50090-4600; 63739-559; 50090-2146; 61442-223; 55154-2081; 65862-078; 45865-877; 71335-0836; 16714-651; 62135-309; 50090-1754; 53104-7518; 68084-070; 68071-4492; 51672-4087; 71335-1347; 50090-3852; 63629-7717; 71205-997; 68071-2440; 71610-109; 51927-0236; 51672-4086; 68071-4576; 68071-3351; 71205-536; 71205-636; 68071-2290; 67296-1696; 50419-758; 12527-8512; 55154-8148; 68071-4627; 63739-700; 55111-010; 71205-649; 72789-065; 61442-224; 55154-2086; 63187-985; 65862-379; 51407-165; 53002-9320
Synonyms Ciprofloxacin | Ciprofloxacin Hydrochloride Anhydrous | Anhydrous, Ciprofloxacin Hydrochloride | Hydrochloride Anhydrous, Ciprofloxacin | Cipro | Ciprofloxacin Hydrochloride | Hydrochloride, Ciprofloxacin | Ciprofloxacin Monohydrochloride Monohydrate | Monohydrate, Ciprofloxacin Monohydrochloride | Monohydrochloride Monohydrate, Ciprofloxacin | Bay-09867 | Bay 09867 | Bay09867 | Ciprinol
Chemical Information
Molecular Formula C17H19ClFN3O3
CAS Registry Number 86483-48-9
SMILES C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Acute hepatic failureAlanine aminotransferase 1P24298Not AvailableNot Available
Acute hepatic failureAspartate aminotransferase, mitochondrialP00505Not AvailableNot Available
DeathDNA gyrase subunit AP48369Not AvailableNot Available
HaematotoxicityAlanine aminotransferase 1P24298Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertonia17.05.02.001; 15.05.04.007--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypotension24.06.03.002--
Injection site reaction12.07.03.015; 08.02.03.014--
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intestinal perforation07.04.06.002--Not Available
Irritability08.01.03.011; 19.04.02.013--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Joint stiffness15.01.02.003--Not Available
Keratitis06.04.02.002--
Keratopathy06.06.03.007--Not Available
Lacrimation increased06.08.02.004--
Laryngeal oedema10.01.05.003; 23.04.01.005; 22.04.02.001--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Lip oedema07.05.04.004; 23.04.01.006; 10.01.05.004--Not Available
Lipase increased13.05.01.003--
Liver function test abnormal13.03.01.013--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Methaemoglobinaemia01.05.01.002--
Migraine24.03.05.003; 17.14.02.001--Not Available
Monocyte count increased13.01.06.009--Not Available
Muscle twitching15.05.03.005--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
The 4th Page    First    Pre   4 5 6 7    Next   Last    Total 7 Pages